BiotechTube

Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination) + Coartem® (arthemether+ lumefantrine)

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Malaria

Conditions

Malaria

Trial Timeline

Sep 1, 2007 → Feb 1, 2009

NCT ID
NCT00540410

About Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination) + Coartem® (arthemether+ lumefantrine)

Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination) + Coartem® (arthemether+ lumefantrine) is a approved stage product being developed by Sanofi for Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT00540410. Target conditions include Malaria.

What happened to similar drugs?

10 of 18 similar drugs in Malaria were approved

Approved (10) Terminated (1) Active (8)
✅COA566NovartisApproved
✅Artesunate-mefloquine + Atovaquone-proguanil + Artemether-lumefantrineNovartisApproved
✅Co-artemetherNovartisApproved
✅Artemether-lumefantrineNovartisApproved
✅Flavoquine®, Camoquin® Suspension + Flavoquine®, Camoquin® SuspensionPfizerApproved
✅Artesunate + Artesunate + Sulfadoxine-Pyrimethamine + arthemether + lumefantrineSanofiApproved
✅Artesunate + AmodiaquineSanofiApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00540410ApprovedCompleted

Competing Products

20 competing products in Malaria

See all competitors
ProductCompanyStageHype Score
SAR97276ASanofiPhase 2
27
SJ733 + CobicistatEisaiPhase 1
29
(+)-SJ000557733 (SJ733)EisaiPhase 2
35
E1018 + PlaceboEisaiPhase 1
36
ZY19489 + Ferroquine (FQ) + PlaceboZydus LifesciencesPhase 1
36
ZY19489 Capsule + Placebo CapsuleZydus LifesciencesPhase 1
29
M5717 330 mg + M5717 500 mg + M5717 660 mg + Pyronaridine 360 mg + Pyronaridine 360 mg + Pyronaridine 540 mg + Pyronaridine 720 mgMerckPhase 2
35
MK-7602 + Artemether/lumefantrine + Primaquine + Artesunate + Atovaquone/proguanilMerckPhase 1
29
M5717 60 mg + Pyronaridine + Atovaquone-Proguanil + M5717 200 mg + M5717 660mgMerckPhase 2
35
KLU156 + CoartemNovartisPhase 3
40
KAF156NovartisPhase 2
35
KAE609 + IV Artesunate + CoartemNovartisPhase 2
35
KAE609NovartisPhase 2
35
artemether:lumefantrine (2.5 mg:30 mg)NovartisPhase 2/3
30
Artemether-lumefantrine (COA566)NovartisPhase 2/3
38
INE963NovartisPhase 2
35
Ganaplacide + ItraconazoleNovartisPhase 1
29
KAE609 + Piperaquine PhosphateNovartisPhase 1
21
Artemether-lumefantrineNovartisPhase 3
40
KAE609 + SoC (Coartem) + KLU156NovartisPhase 2
35